Latest News
Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
WASHINGTON, D.C. and NEW YORK February 6, 2012 – Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer. The collaboration will explore the capabilities of Exosome RNA biofluid-based diagnostic technology for early identification, progression monitoring and disease risk stratification in glioma, the most common form of brain cancer. More…
EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
MUNICH February 1, 2012 - Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announce the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagnostic tests from the stable RNA content accessible in plasma-derived exosomes. The grant will help fund development of exosome-based diagnostics technology to detect tumor specific mutations in the blood from patients with malignant cancer in order to enable monitoring of disease recurrence, aid therapy selection and possibly improve early tumor detection. The grant was awarded under the Munich Leading-Edge Cluster Program "m4 — Personalized Medicine and Targeted Therapies". More…
The Prostate Cancer Foundation and Exosome Diagnostics Collaborate to Accelerate Clinical Validation of Exosome Biofluid Molecular Diagnostics in Prostate Cancer
SANTA MONICA, CA and NEW YORK, NY (USA) October 13, 2011 – The Prostate Cancer Foundation (PCF) and Exosome Diagnostics today are announcing a multi-year collaboration to accelerate clinical validation of Exosome’s biofluid molecular diagnostics technology in prostate cancer. In addition, Howard Soule, PhD, chief science officer of PCF, will join the Exosome Diagnostics Scientific Advisory Board. More…
Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology
NEW YORK (NY, USA) October 3, 2011 – Exosome Diagnostics, Inc. today announced the appointment of' David Okrongly, PhD, as chief operating officer, Michael Donovan, MD, PhD, as chief medical officer, and Sally Bowden as director of regulatory affairs. The company also welcomed new members to its Scientific Advisory Board. More…
Exosome Diagnostics Announces Expansion of Scientific Advisory Board
NEW YORK (NY, USA) May 24, 2011 — Exosome Diagnostics, Inc. today announced the appointments of Bob Carter MD, PhD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB). More…
Key Genes Associated with Cancer Found in Circulating Blood Microvesicles
NEW YORK (NY, USA), MUNICH (GERMANY) February 3, 2011 — Exosome Diagnostics, Inc. today announced a study published in Nature Communications by researchers at Massachusetts General Hospital/Harvard Medical School show that tumor microvesicles contain retro-transposons, also known as "jumping genes" as well as amplified oncogene sequences. These discoveries expand further on the use of microvesicles such as exosomes as a powerful blood-based cancer diagnostic medium. More…